Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke

Phase 1

Recruiting

• Conditions: Cognitive Impairment
• Interventions: Drug: Pentoxifylline

• Registration Number: NCT06344390
• Lead Sponsor: The First Hospital of Hebei Medical University

Brief Summary

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.

Detailed Description

Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function.

Study Timeline

• Study First Submitted: 2023-12-25
• Status Verified: 2024-03
• Study First Submitted QC: 2024-03-27
• Last Update Submitted: 2024-03-27
• Study First Posted: 2024-04-03
• Last Update Posted: 2024-04-03
• Study Start: 2024-04-10
• Primary Completion: 2024-10-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Han Chinese, age 40-80 years old, male and female, right-handed;
• The diagnosis is consistent with the Expert Consensus on the Management of Cognitive Impairment after Stroke 2021;
• NIHSS score 1-15 points;
• Daily Living Ability Scale (ADL) ≥75 score;
• The Informed consent signed by the patient or his legal representative

Exclusion Criteria

• Can not cooperate with the examination (including neuropsychological tests and scale assessment);
• There were memory disorders, dementia with lewy bodies and frontotemporal dementia before the onset of stroke events;
• There were definite infectious diseases 2 weeks before admission; Have a serious mental illness, previous history of cancer, alcohol or drug abuse;
• Use of drugs that may affect cognitive function, including sedatives, anti-anxiety drugs, hypnotics, nootropic drugs, and cholinoid drugs;
• Can not accept brain MRI examination

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pentoxifylline	Pentoxifylline	Pentoxifylline

Primary Outcome Measures

Name	Time	Method
Pentoxifylline can improve cognitive impairment after ischemic stroke	3 months	The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment.If the score is less than 26 points, it is considered to have cognitive impairment.Patient scores get higher after 3 months, we think pentoxifylline can improve cognitive impairment after ischemic stroke.

Trial Locations

Locations (1)

BHan; 🇨🇳 Shijiazhuang, China